Manta Ray #UUV prototype completes full-scale, in-water testing off the coast of SoCal. DARPA program exhibits modular, first-of-kind capability for an extra-large uncrewed underwater vehicle. Built by Northrop Grumman. darpa.mil/news-events/20…

My prediction stands: the bioeconomy will surpass the tech economy in impact and scale. I first discussed this at SynBioBeta 2022 and was inspired by the passionate entrepreneurs I met there. This year, the top minds in synthetic biology will gather in San Jose, May 6-9. Don’t…

Good coverage of reef challenges and solutions by the University of Miami #REEFENSE team supported by DARPA

Welcoming Pixium Vision’s PRIMA retinal prosthesis to Science

science.xyz/news/pixium-vi…

Stephen Wolfram, the mind behind Wolfram Research, and Brian Frezza, the founder of Emerald Cloud Labs, will be joining us at #SynBioBeta2024 to discuss the intersection of automated laboratories and #AI and how these technologies are advancing scientific discovery. Join us on…

By spinning clinical flu program back out from partner JNJ into itself, Cidara has renewed purpose & becomes first fledgling to take flight from RA Capital’s Project Condor. 

What’s Condor? More on that, the Cidara deal, & other things w/ bird names & big plans here……

Michael Koeris Jason Kelly John Cumbers DARPA Congrats Mike 👌

I think you can also put something else in the middle - maybe something with 5 letters...

Joking aside - I do very much appreciate what #FRO #focusedresearchorganizations have to offer the nation and the world. Kudos Schmidt Futures for supporting those!

CC Thomas Kalil

Thank you so much Emily Leproust 🙏

Onwards and upwards - anyone have good ideas to create and anticipate #StrategicSurprise for the nation, ping me; that's DARPA's mission

.Michael Koeris was just named the new head of DARPA's Biological Technologies Office. This is significant because DARPA has a budget of over $4 billion and has been investing in synthetic biology for the past decade.  Mike also comes from the lab of Jim Collins, one of the founding…

Stanford Management Co ($40 billion endowment) is hiring a Managing Director of Stakeholder Engagement: $400k - $575k

@stanford USC UC Berkeley University of Washington UT Austin UNC Kenan-Flagler Chicago Booth Duke Fuqua MIT Sloan School of Management Yale SOM NYU Stern Princeton University Darden School at UVA FLORIDA

allocatorjobs.com/managing-direc…

Cantor's Eric Schmidt writes an interesting thought piece today on liked vs unliked biotech CEOs -- and whether investors would be smart to consider owning stocks run by the latter.

Schmidt writes:

But what if we have it all wrong? What if our desire to find a CEO “likeable”…

Reddit is freaking out over LLaMA 3

I’m excited to welcome Packy McCormick and Elliot Hershberg back to #SynBioBeta2024 . I’m a big fan of both of their newsletters. Packy writes the Not Boring Newsletter and is the founder of Not Boring Capital, and Elliot writes The Century of Biology. They are both active #investors ,…

'You can't achieve greatness by doing what everyone else is doing.

If your choices resemble those of your friends, you'll get the same results they get.'

— A tiny thought in the FS weekly newsletter. fs.blog/newsletter

Big news for Pearl Bio! Proud to be the first check in! 🧬

There are 50+ synthetic biology investment funds coming to SynBioBeta this year! If you’re a synthetic biology #startup raising money right now, check 'em out below: synbiobeta.com/attend/synbiob…

2048 Ventures
age1
Ajinomoto Corporate Venture Capital
ARK Investment Management LLC…

I met today with this incredible group of Stanford students who are interested in defensetech, and in protecting our national security and interests.

Two things to note:
1) several had served in the military or related. Impressive backgrounds. So glad they are interested in the…

insitro CEO and Founder, Daphne Koller spoke with Eric Topol of Ground Truths podcast to talk about the intersection of AI and life sciences, the tremendous power and potential it has, and how the convergence may change the landscape of medicine. Hear the conversation below.

David Grainger All existing shareholders should be concerned about over-dilutive stock offerings/issuances (including excessive evergreen option reloads), balanced with survival (and the ability to fund programs), obviously. Dilution is just one component of the equation to maximize value.…